Laser differential light-scattering bioassay for methotrexate (NSC-740)

Area of Science:

• Biotechnology and Biomedical Assays
• Pharmacokinetics and Drug Monitoring

Background:

• Traditional methods for antitumor drug quantification can be time-consuming and complex.
• Bacterial light-scattering patterns have shown promise for rapid antibiotic sensitivity testing.
• A need exists for faster, more accessible methods to monitor antitumor drug levels in patients.

Purpose of the Study:

• To develop and validate a new bioassay for estimating antitumor drugs in biological samples.
• To assess the feasibility of using laser light scattering for drug concentration measurements.
• To evaluate the assay's performance for methotrexate in serum and urine samples.

Main Methods:

• A bioassay was developed using laser light scattering from drug-sensitive bacterial suspensions.
• The method was applied to quantify antitumor drugs, including methotrexate, in small sample volumes (0.1 ml).
• Assay results were compared with standard disc-diffusion and radioisotopic assays for validation.

Main Results:

• The laser light scattering method demonstrated sensitivity for drug concentrations as low as nanograms per milliliter.
• Accurate assay results for methotrexate in human and dog serum were obtained within 3 hours.
• Time-dependent serum levels and urinary excretion rates correlated well across different assay methods.

Conclusions:

• Laser light scattering offers a rapid and sensitive bioassay for antitumor drug estimation.
• This method provides timely pharmacokinetic data for drugs like methotrexate.
• The technique has potential for clinical application in therapeutic drug monitoring.